patent/CN-103370314-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103370314-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b70512b2076a2759fccaecf9fe962d5
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04
filingDate	2011-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99946b15148bd9668e66431800acc280 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_965f154cee3281aa69f371f744ef9907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f5788d18de2d0f834367442553f9d23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d816929a26b9fd7b13d49bcfbab9cf63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bd6ea84e71bc03f83dc6cb7534ba443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89ef461c4bcc72ee18bea1af445afbc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0077d4032f3b8c2741e981879f3135a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cdab07f56699c94cfb5c14ab3eef5a1
publicationDate	2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-103370314-A
titleOfInvention	Substituted benzopyrazine derivatives as FGFR kinase inhibitors for the treatment of cancer diseases
abstract	The present invention relates to a novel quinoxaline derivative compound, to a pharmaceutical composition containing the compound, to a preparation method of the compound and to the use of the compound in the treatment of diseases, such as cancer.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114174271-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108026588-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021023194-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108137546-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11680061-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108137546-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114174271-A
priorityDate	2010-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009019518-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466823773 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467857426

Total number of triples: 36.